Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





AI Takes Guesswork Out Of Lateral Flow Testing

By LabMedica International staff writers
Posted on 19 Oct 2022

An artificial intelligence (AI) app to read COVID-19 lateral flow tests helped to reduce false results in a new trial. More...

A team of researchers from the University of Birmingham (Birmingham, UK), Durham University (Durham, UK) and Oxford University (Oxford, UK) tested whether a machine learning algorithm could improve the accuracy of results from antigen lateral flow devices for COVID-19. The LFD AI Consortium team worked at UK Health Security Agency assisted test centres and with health care workers conducting self-testing to trial the AI app. More than 100,000 images were submitted as part of the study, and the team found that the algorithm was able to increase the sensitivity of results, determining between a true positive and false negative, from 92% to 97.6% accuracy.

“The widespread use of antigen lateral flow devices was a significant moment not just during the pandemic, but has also introduced diagnostic testing to many more people in society. One of the drawbacks with LFD testing for COVID, pregnancy and any other future use is the ‘faint line’ question – where we can’t quite tell if it’s a positive or not,” said Professor Andrew Beggs, Professor of Cancer Genetics & Surgery at the University of Birmingham and lead author of the study. “The study looked at the feasibility of using machine learning to take the guesswork out of the faint line tests, and we’re pleased to see that the app saw an increase in sensitivity of the tests, reducing the numbers of false negatives. The promise of this type of technology could be used in lots of applications, both to reduce uncertainty about test results and provide a crucial support for visually impaired people.”

“The increase in sensitivity and overall accuracy is significant and it shows the potential of this app by reducing the number of false negatives and future infections. Crucially, the method can also be easily adapted to the evaluation of other digital readers for lateral flow type devices,” added Professor Camila Caiado, Professor of Statistics at Durham University and chief statistician on the project.

Related Links:
University of Birmingham
Durham University
Oxford University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.